您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > PD-1/PD-L1 Inhibitor 3
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
PD-1/PD-L1 Inhibitor 3
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
PD-1/PD-L1 Inhibitor 3图片
CAS NO:1629654-95-0
规格:98%
分子量:1852.17
包装与价格:
包装价格(元)
1mg电议
5mg电议

产品介绍
PD-1/PD-L1 interaction inhibitor
CAS:1629654-95-0
分子式:C89H126N24O18S
分子量:1852.17
纯度:98%
存储:Store at -20°C

Background:

PD-1/PD-L1 Inhibitor 3 is a PD-1/PD-L1 interaction inhibitor.


The anti-PD-1 and anti-PD-L1 compounds have been found to show impressive antitumor effects in various malignancies, such as melanoma. The greatest clinical outcome in unselected patients has been observed in melanoma. The tumor expression of PD-L1 is suggested to be a suggestive, inadequate, and predictive of response to immune-checkpoint blockade.


In vitro: PD-1/PD-L1 inhibitor 3 has been identified to be a potent and selective small molecule inhibitor blocking the interaction of programmed cell death protein 1 (PD-1) with its ligand protein (PD-L1) and with CD80. PD-1/PD-L1 inhibitor 3 was also found to act as an immunomodulator. In addition, PD-1/PD-L1 Inhibitor 3 was found to have highly efficacious binding to PD-L1 and promote the increased functional activities of T cells. Therefore, PD-1/PD-L1 inhibitor 3 could be regarded as a promising therapeutic treatment of cancer and infectious diseases, such as hepatitis C [1].


In vivo: So far, there is no animal in vivo study reported for PD-1/PD-L1 Inhibitor 3.


Clinical trial: Up to now, PD-1/PD-L1 Inhibitor 3 is still in the preclinical development stage.


参考文献:
[1] MILLER Michael Matthew, et al.? Patent, Pub. No.:WO/2014/151634